A Year at NCI: Harold Varmus Reflects On Provocative Questions, The Duke Scandal, Financial Disaster And Grant Review
Part One Of A Two-Part Interview With NCI Director Harold Varmus
Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication
ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications
Richard Pazdur’s Comments to ODAC
Department of Defense Offering $16 Million in Cancer Research Grants
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya